The Tyrosol to Hydroxytyrosol Conversion: A Human RCT

The cardiovascular benefits of olive oil have long been attributed to its polyphenols, with hydroxytyrosol typically singled out as the most active compound. In 2019, Boronat and colleagues published a randomized crossover trial in Free Radical Biology and Medicine showing that the related olive phenol tyrosol is itself converted into hydroxytyrosol inside the human body -- and that the conversion produces measurable cardiovascular benefits even when tyrosol is delivered alone.

Why This Study Matters

Olive oil contains a family of phenolic compounds, and most of the attention has gone to hydroxytyrosol because it has the strongest in vitro antioxidant activity. Tyrosol, a structurally simpler phenol present in larger amounts than hydroxytyrosol in most olive oils, has often been treated as a less potent companion molecule.

Preclinical studies suggested something more interesting: cytochrome P450 enzymes -- specifically CYP2A6 and CYP2D6 -- can hydroxylate tyrosol to produce hydroxytyrosol inside the body. If that conversion happens in humans at meaningful rates, it changes how the olive polyphenol story should be told. Tyrosol would not be a junior cousin to hydroxytyrosol but a partial precursor to it.

The Boronat 2019 trial was designed to test three linked questions in humans: does tyrosol convert to hydroxytyrosol in vivo, does that conversion produce cardiovascular benefits, and does the rate of conversion depend on the participant's genetics? The third question is the most clinically interesting -- if CYP2A6 and CYP2D6 polymorphisms determine how efficiently a person makes hydroxytyrosol from dietary precursors, that could explain some of the heterogeneity seen in olive polyphenol trials.

How It Was Designed

Thirty-three individuals at elevated cardiovascular risk were enrolled in a randomized crossover trial with three intervention arms. In random order, each participant completed three intervention periods: white wine (1 standard drink/day for women, 2 for men), white wine plus tyrosol capsules (25 mg of tyrosol per drink), and water (control), all consumed ad libitum within the prescribed limits.

The crossover design means each participant served as their own control. Randomization of arm order minimizes order effects, and washout periods between arms reduce carryover.

Participants were genotyped for CYP2A6 and CYP2D6 polymorphisms and classified by a polygenic activity score (PAS) into low versus normal activity metabolizers. This is the genetics layer that lets the analysis test whether individual variation in conversion enzymes affects how much hydroxytyrosol gets generated from a given dose of tyrosol.

Outcomes measured included urinary hydroxytyrosol recovery (the direct biomarker of tyrosol-to-hydroxytyrosol conversion), endothelial function, plasma HDL cholesterol, antithrombin III, homocysteine, endothelin-1, soluble CD40 ligand, and gene expression of vascular signaling molecules (P65/RELA, CFH, iNOS, eNOS, VEGFA) in peripheral blood mononuclear cells.

What They Found

The conversion occurred, the genetics modulated the rate, and the cardiovascular benefits followed.

Marker	Wine + Tyrosol	Wine Alone / Control	p-value	What It Measures
Urinary HT recovery	Higher	Lower	< 0.05	Tyrosol-to-HT conversion
Endothelial function	Improved	No improvement	< 0.05	Vascular reactivity
HDL cholesterol	Increased	No increase	< 0.05	Good cholesterol
Homocysteine	Decreased	No decrease	< 0.05	Vascular risk amino acid
Endothelin-1	Decreased	No decrease	< 0.05	Vasoconstrictor signaling
CD40L, P65/RELA, CFH	Reduced expression	No reduction	< 0.05	Inflammation signaling

Green indicates a favorable effect of tyrosol supplementation (added to white wine) versus wine alone or water control. All effects significant at p<0.05.

Reading the Results

The conversion is real and measurable in humans. Urinary hydroxytyrosol recovery after the wine-plus-tyrosol intervention was significantly higher than after wine alone or water. That is the direct biomarker proof that the body converts ingested tyrosol into hydroxytyrosol under normal physiological conditions.

Genetics modulate the conversion rate. Individuals classified as low-activity metabolizers by the CYP2A6/CYP2D6 polygenic activity score had lower hydroxytyrosol-to-tyrosol ratios than normal-activity metabolizers. This is exactly the pattern you would expect if those cytochrome P450 enzymes are the rate-limiting step. It also has practical implications: a portion of the population may convert dietary olive precursors less efficiently and therefore derive less benefit from precursor-rich oils.

The cardiovascular signal followed the conversion. Endothelial function improved. HDL cholesterol rose. Antithrombin III rose. Homocysteine, endothelin-1, and soluble CD40 ligand all decreased. Gene expression of pro-inflammatory and vascular signaling molecules in peripheral blood mononuclear cells decreased. These changes span the major pathways implicated in cardiovascular disease -- vascular tone, lipid metabolism, thrombosis, and inflammation -- and they appeared in the arm where the body was actively converting tyrosol to hydroxytyrosol.

Tyrosol can blunt some adverse effects of wine. Wine alone increased expression of iNOS, eNOS, VEGFA, and CHF in peripheral blood mononuclear cells -- changes that the authors framed as part of the broader vascular response to alcohol. Adding tyrosol capsules to wine abolished those increases. This is mechanistically interesting because it suggests tyrosol's effect is not just additive to wine but actively counterbalances some of wine's vascular signaling.

What Didn't Change

This trial used 33 participants, which is small. Crossover designs gain statistical efficiency by having each participant serve as their own control, but the overall sample remains modest, particularly for the genetics subgroup analyses. The findings on the CYP2A6/CYP2D6 activity score are best treated as hypothesis-generating for now.

The intervention combined tyrosol with wine, which means the effects are technically measured in the context of moderate alcohol consumption. Tyrosol without wine was not tested as a separate arm. Whether tyrosol delivered through a non-alcoholic vehicle would produce the same cardiovascular signal cannot be answered by this design.

The trial duration was short by chronic disease standards. The cardiovascular markers measured here are intermediate biomarkers, not hard endpoints like heart attack or stroke. Demonstrating biomarker improvement is necessary but not sufficient to establish clinical benefit at scale.

Broader Context

This trial sits within a broader literature establishing the bioactivity of olive polyphenols. The PREDIMED randomized trial showed that extra virgin olive oil rich in polyphenols, consumed within a Mediterranean diet, reduced major cardiovascular events by approximately 30% over 4.7 years. Multiple intervention studies with isolated hydroxytyrosol have shown reductions in oxidized LDL, inflammation markers, and DNA damage at doses ranging from 5 to 45 mg/day.

In 2011, the European Food Safety Authority authorized a health claim for olive oil polyphenols and the protection of blood lipids from oxidative damage, requiring at least 5 mg of hydroxytyrosol and its derivatives per 20 g of olive oil daily. Importantly, the EFSA claim specifies hydroxytyrosol "and its derivatives," implicitly recognizing that the active pool includes precursor compounds that convert in vivo. The Boronat 2019 trial gives that regulatory language an explicit human mechanism: tyrosol is one of those convertible precursors.

The genetics finding deserves further work. If CYP2A6 and CYP2D6 polymorphisms substantially modulate how much hydroxytyrosol an individual can produce from dietary precursors, that helps explain heterogeneity in olive polyphenol trials and points toward personalized supplementation strategies for individuals with lower endogenous conversion capacity.

Related Research

Continue exploring olive oil and polyphenol science:

• Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation
• EUROLIVE: Olive Polyphenols Raise HDL -- The Foundational Trial
• Hydroxytyrosol-Enriched Bread Improved HbA1c in T2D Adults

Source: View the original study on PubMed

Olivea's Dosage

This trial used 25 mg of tyrosol per standard drink, with most participants receiving 1 to 2 doses per day. The effective hydroxytyrosol exposure depends on individual CYP2A6/CYP2D6 activity. Olivea's approach skips the conversion step: each Olivea capsule delivers hydroxytyrosol directly, removing the dependence on individual enzyme activity. Our most recent third-party certificate of analysis confirmed 23.5 mg of hydroxytyrosol per capsule.

According to PubMed, this study is indexed as PMID 31479717 (DOI: 10.1016/j.freeradbiomed.2019.08.032).

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.